Drug intelligence / Profile preview

DERMAL-PPGV-CAN

Development stage: Preclinical
Lead developer: PharmaPlanter Technologies
Modality: Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Topical

Overview

DERMAL-PPGV-CAN is a personalized cancer vaccine candidate developed by PharmaPlanter Technologies. It utilizes a proprietary Gas Vesicle Nanoparticle (GVNP) platform to deliver patient-specific tumor neoantigens. The vaccine is designed for dermal (topical) administration, aiming to leverage the skin's immune-rich environment to activate anti-tumor T-cell responses. It is currently in preclinical development for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL).

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on DERMAL-PPGV-CAN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DERMAL-PPGV-CAN.

Explore the full profile